Edition:
United States

Astellas Pharma Inc (4503.T)

4503.T on Tokyo Stock Exchange

1,512JPY
19 Apr 2019
Change (% chg)

¥-4 (-0.26%)
Prev Close
¥1,516
Open
¥1,518
Day's High
¥1,526
Day's Low
¥1,503
Volume
2,917,000
Avg. Vol
6,359,574
52-wk High
¥2,056
52-wk Low
¥1,356

About

Astellas Pharma Inc. is a Japan-based company mainly engaged in the research, development, manufacture and sales of pharmaceutical products. The Company is involved in the manufacture and sale of pharmaceutical products in Japan, the United States, Europe, China, Korea, Taiwan and other markets through its subsidiaries. Its main... (more)

Overall

Beta: 0.71
Market Cap(Mil.): ¥3,000,422.00
Shares Outstanding(Mil.): 1,979.82
Dividend: 19.00
Yield (%): 2.44

Financials

  4503.T Industry Sector
P/E (TTM): 13.84 57.23 57.80
EPS (TTM): 109.53 -- --
ROI: 14.38 12.21 11.82
ROE: 16.07 13.15 12.64

Astellas, Eli Lilly must face lawsuit alleging underpaid Medicaid rebates

Astellas Pharma and Eli Lilly and Co must face a whistleblower lawsuit accusing them of knowingly underpaying rebates they owed to state Medicaid programs, a federal judge has ruled.

Apr 04 2019

Swiss stocks - Factors to watch on Dec 10

ZURICH/BERLIN, Dec 10 The Swiss blue-chip SMI was seen opening 0.9 percent lower at 8,659 points on Monday, according to premarket indications by bank Julius Baer .

Dec 10 2018

Astellas Pharma gets U.S. nod for blood cancer treatment

The U.S. Food and Drug Administration on Wednesday approved a blood cancer treatment from Japan's Astellas Pharma Inc, making it the first targeted therapy to treat patients with a certain mutation.

Nov 28 2018

UPDATE 2-Astellas Pharma gets U.S. nod for blood cancer treatment

Nov 28 The U.S. Food and Drug Administration on Wednesday approved a blood cancer treatment from Japan's Astellas Pharma Inc, making it the first targeted therapy to treat patients with a certain mutation.

Nov 28 2018

Astellas Pharma gets U.S. nod for blood cancer treatment

Nov 28 Japan's Astellas Pharma Inc on Wednesday received approval from the U.S. Food and Drug Administration for its blood cancer treatment, according to the regulator's website https://bit.ly/2SjB8CL.

Nov 28 2018

Earnings vs. Estimates